Ho presentato la mia candidatura online. La procedura ha richiesto 4 settimane. Ho sostenuto un colloquio presso PriceSpective (Los Angeles, CA) nel mese di mag 2013
Colloquio
Over a period of 4 weeks I had a 30 min phone screener, 60 minute phone interview with a Director, than a multiple hours in person day with 3 1:1 interviews. the first was for fit, second with a case example, and last with VP that allowed me to direct the conversation more than the rest.
Ho presentato la mia candidatura tramite l'università. Ho sostenuto un colloquio presso PriceSpective
Colloquio
Talked with recruitment table and career fair, and they called me the next day to interview through my school's OCR program.
Interview was typical behavioral + case study, they asked why pharma, why consulting, what past experience do I have etc.
Domande di colloquio [1]
Domanda 1
What should we price this drug based on the competition and insurance/copay factors for patients
Ho presentato la mia candidatura online. Ho sostenuto un colloquio presso PriceSpective (Londra, Inghilterra) nel mese di ott 2013
Colloquio
1. Phone interview with HR-general questions on yourself and why you chose the company
2. Face to face interview with senior consultant/director (competency based questions + questions derived from your resume) + 1 case study.
3. Face to face interview with VP/Associate Director (competency based questions) + 1 case study.
4. Case study presentation-given in advance (one week in advance) for you to prep and questions about it after.
#1 happened 2 weeks after the online application was made. #2-#4 all happened on the same day as the company did not have time to schedule it all on different days.
Domande di colloquio [1]
Domanda 1
Case Question 1: Market sizing, pricing of a drug. This is the question: A large pharma company is expecting EMA approval for a therapy that treats lower respiratory infections i.e. Drug Y (which is an antibiotic). In about six months the division will receive EMA approval to launch drug. Despite this apparent good news from the EMA, the EU division is concerned about the market potential for drug Y and it’s ability to reach key prescribers in the therapeutic category.
You have been asked to help them determine the commercial value of this product and the likelihood of use, and determining whether they should:
Launch alone
Co-market with a partner (Joint venture)
Sell or license the drug
The concerns over market potential centre on whether the drug can gain adequate competitive advantage in a market segment having a dominant, patent-protected competitor and low cost generic antibiotics. Additionally, a higher technology antibiotic, which appears to offer therapeutic advantages was recently introduced by a competitor.
Case Question 2: Putting a drug into a market, IP issues and should they proceed or not.
Case Question 2 was more difficult than case question 1.